Pfizer's Tick-Borne Encephalitis Vaccine Gets Priority Review Tag In US

The FDA has accepted Pfizer Inc's (NYSE: PFE) marketing application seeking approval for TicoVac under priority review status. TicoVac is the tick-borne encephalitis (TBE) vaccine for active immunization in individuals aged one and older.
The anticipated action date is expected for August 2021.
TBE is a viral infection of the brain and spine, transmitted to humans through the bite of an infected tick.
The company's TBE vaccine is already marketed in Europe under the brand names TicoVac and FSME-Immun.
Price Action: PFE is up 0.12% at $33.95 in premarket trading on the last check Wednesday.

Momentum29.11

Growth78.79

Quality46.84

Value31.18

Short

Medium

Long